P
39.82
1.27 (3.29%)
| 前收盘价格 | 38.55 |
| 收盘价格 | 39.04 |
| 成交量 | 242,260 |
| 平均成交量 (3个月) | 461,298 |
| 市值 | 811,093,568 |
| 价格/销量 (P/S) | 107.42 |
| 股市价格/股市净资产 (P/B) | 2.05 |
| 52周波幅 | |
| 利润日期 | 11 Aug 2025 - 15 Aug 2025 |
| 营业利益率 (TTM) | -2,868.84% |
| 稀释每股收益 (EPS TTM) | -10.66 |
| 季度收入增长率 (YOY) | 1,349.10% |
| 总债务/股东权益 (D/E MRQ) | 0.24% |
| 流动比率 (MRQ) | 8.44 |
| 营业现金流 (OCF TTM) | -163.91 M |
| 杠杆自由现金流 (LFCF TTM) | -90.04 M |
| 资产报酬率 (ROA TTM) | -39.95% |
| 股东权益报酬率 (ROE TTM) | -63.56% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Praxis Precision Medicines, Inc | 看跌 | 看跌 |
AIStockmoo 评分
0.5
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.50 |
|
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.16% |
| 机构持股比例 | 122.04% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 105.00 (HC Wainwright & Co., 163.69%) | 购买 |
| 中 | 80.00 (100.90%) | |
| 低 | 28.00 (Wedbush, -29.68%) | 卖出 |
| 平均值 | 78.00 (95.88%) | |
| 总计 | 4 购买, 1 卖出 | |
| 平均价格@调整类型 | 39.99 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 12 Jun 2025 | 80.00 (100.90%) | 购买 | 45.03 |
| 05 May 2025 | 80.00 (100.90%) | 购买 | 38.96 | |
| Oppenheimer | 02 Jun 2025 | 97.00 (143.60%) | 购买 | 39.82 |
| Chardan Capital | 07 May 2025 | 80.00 (100.90%) | 购买 | 38.09 |
| Wedbush | 05 May 2025 | 28.00 (-29.68%) | 卖出 | 38.96 |
| HC Wainwright & Co. | 01 May 2025 | 105.00 (163.69%) | 购买 | 38.06 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合